Tan Zhi-Qin, Liu Fu-Xiang, Tang Hai-Lin, Su Qi
Department of Obstetrics and Gynecology, the 169th Hospital of PLA, Hengyang of Hunan Province 421002, China.
Zhonghua Fu Chan Ke Za Zhi. 2010 Oct;45(10):772-4.
to investigate the expression of the hsa-miR-155 in serum of endometrial cancer and its clinical significance.
collected 44 cases blood specimens before surgery operation from Sep. 2008 to Dec. 2009, and collected 12 cases blood specimens from the health of volunteers in comparison. Real time quantity PCR was used to detect the expression of hsa-miR-155 in those specimens and analyzed clinical pathological with the expression of hsa-mir-155 in endometrial cancer.
the expression of hsa-miR-155 was (3.9 ± 0.7) in endometrial cancer, which was significantly higher than that in control group (P < 0.01). The expressions of hsa-miR-155 were (3.7 ± 0.6), (3.9 ± 0.6) and (3.7 ± 0.6) times in well, moderately and poorly differentiated endometrial cancer, respectively, while there were not significant difference (P > 0.05). The expressions were (3.8 ± 0.6) and (3.9 ± 0.6) times between endometrioid adenocarcinoma and non-endometrioid adenocarcinoma, and there were significant difference (P > 0.05). The expressions were (2.1 ± 0.4) and (5.6 ± 0.8) times in stage I - II and III - IV endometrial cancer, respectively, in which there were significant difference (P < 0.05). The expressions of hsa-miR-155 were (5.5 ± 0.5) and (1.9 ± 0.2) times between lymph node metastasis and without lymph node metastasis in endometrial cancer, in which there were significant difference (P < 0.01).
Hsa-miR-155 may play an important role in the proliferation, and metastasis of endometrial cancer, which may be a indicator in the diagnosis and prognosis of endometrial cancer and may be used as a predictive biomarker.
探讨人微小RNA-155（hsa-miR-155）在子宫内膜癌患者血清中的表达及其临床意义。
收集2008年9月至2009年12月手术前44例子宫内膜癌患者的血液标本，并收集12例健康志愿者的血液标本作为对照。采用实时定量聚合酶链反应（Real time quantity PCR）检测上述标本中hsa-miR-155的表达，并分析其与子宫内膜癌临床病理特征的关系。
子宫内膜癌患者血清中hsa-miR-155的表达量为（3.9±0.7），显著高于对照组（P<0.01）。高分化、中分化及低分化子宫内膜癌患者血清中hsa-miR-155的表达量分别为（3.7±0.6）、（3.9±0.6）及（3.7±0.6）倍，差异无统计学意义（P>0.05）。子宫内膜样腺癌和非子宫内膜样腺癌患者血清中hsa-miR-155的表达量分别为（3.8±0.6）和（3.9±0.6）倍，差异无统计学意义（P>0.05）。Ⅰ-Ⅱ期和Ⅲ-Ⅳ期子宫内膜癌患者血清中hsa-miR-155的表达量分别为（2.1±0.4）和（5.6±0.8）倍，差异有统计学意义（P<0.05）。有淋巴结转移和无淋巴结转移的子宫内膜癌患者血清中hsa-miR-155的表达量分别为（5.5±0.5）和（1.9±0.2）倍，差异有统计学意义（P<0.01）。
hsa-miR-155可能在子宫内膜癌的增殖和转移中发挥重要作用，有望成为子宫内膜癌诊断及预后判断的指标，并可作为预测生物标志物。
